These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36293049)

  • 1. PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer's Disease.
    Papotti B; Adorni MP; Marchi C; Zimetti F; Ronda N; Panighel G; Lupo MG; Vilella A; Giuliani D; Ferri N; Bernini F
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.
    Picard C; Poirier A; Bélanger S; Labonté A; Auld D; Poirier J;
    PLoS One; 2019; 14(8):e0220254. PubMed ID: 31437157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
    Zimetti F; Caffarra P; Ronda N; Favari E; Adorni MP; Zanotti I; Bernini F; Barocco F; Spallazzi M; Galimberti D; Ricci C; Ruscica M; Corsini A; Ferri N
    J Alzheimers Dis; 2017; 55(1):315-320. PubMed ID: 27662294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
    J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9.
    Choi S; Aljakna A; Srivastava U; Peterson BR; Deng B; Prat A; Korstanje R
    Lipids Health Dis; 2013 Jul; 12():112. PubMed ID: 23883163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
    Ferri N; Corsini A; Macchi C; Magni P; Ruscica M
    Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 ablation attenuates Aβ pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice.
    Vilella A; Bodria M; Papotti B; Zanotti I; Zimetti F; Remaggi G; Elviri L; Potì F; Ferri N; Lupo MG; Panighel G; Daini E; Vandini E; Zoli M; Giuliani D; Bernini F
    Brain Behav Immun; 2024 Jan; 115():517-534. PubMed ID: 37967665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid beta increases ABCA1 and HMGCR protein expression, and cholesterol synthesis and accumulation in mice neurons and astrocytes.
    Azizidoost S; Babaahmadi-Rezaei H; Nazeri Z; Cheraghzadeh M; Kheirollah A
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Jan; 1867(1):159069. PubMed ID: 34744007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
    Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
    J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer's disease.
    Rolyan H; Feike AC; Upadhaya AR; Waha A; Van Dooren T; Haass C; Birkenmeier G; Pietrzik CU; Van Leuven F; Thal DR
    J Neural Transm (Vienna); 2011 May; 118(5):699-712. PubMed ID: 21210284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
    Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
    Miranda MX; van Tits LJ; Lohmann C; Arsiwala T; Winnik S; Tailleux A; Stein S; Gomes AP; Suri V; Ellis JL; Lutz TA; Hottiger MO; Sinclair DA; Auwerx J; Schoonjans K; Staels B; Lüscher TF; Matter CM
    Eur Heart J; 2015 Jan; 36(1):51-9. PubMed ID: 24603306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2.
    Chae HS; Pel P; Cho J; Kim YM; An CY; Huh J; Choi YH; Kim J; Chin YW
    J Ethnopharmacol; 2021 Oct; 278():114265. PubMed ID: 34111537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 20(
    Huang YW; Zhang M; Wang LT; Nie Y; Yang JB; Meng WL; Wang XJ; Sheng J
    Food Funct; 2022 Jul; 13(13):7020-7028. PubMed ID: 35723202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.